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Abstract: The early work on neuropeptide-monoamine receptor-receptor interactions in the Central Nervous System 
gave the first indications of the existence of G protein-coupled receptors (GPCRs) heteroreceptor complexes and the 
GPCR field began to expand from monomers into heteromers and higher order heteromers, including also GPCR-ion 
channel, Receptor Tyrosine Kinases (RTK)-GPCR and Receptor activity-modifying proteins-GPCR heteroreceptor 
complexes. The existence of heteroreceptor complexes with allosteric receptor-receptor interactions increases the 
diversity of receptor function including recognition, trafficking and signalling. We have proposed the molecular 
phenomenon of receptor-receptor interactions as a good way to understand of how brain function can increase through 
molecular integration of signals. An alteration in specific receptor-receptor interactions or their balance/equilibrium (with 
the corresponding monomers-homomers) are indeed considered to have a role in the pathogenic mechanisms that lead 
to various diseases, including drug addiction, depression, Parkinson's disease and schizophrenia. Therefore, targeting 
protomer-protomer interactions in heteroreceptor complexes or the balance with their corresponding homoreceptor 
complexes in discrete brain regions may become an important field for developing novel drugs, including heterobivalent 
drugs and optimal types of combined treatments. Increasing our understanding of molecular integration of signals via 
allosteric receptor-receptor interactions in the heteroreceptor complexes will have a major impact on the molecular 
medicine, leading to novel strategies for drug discovery and treatment of diseases. 
Keywords: G protein-coupled receptors, Dimerization, Oligomerization, Homdimer, Heterodimer, Homoreceptor 
complexes, Heteroreceptor complexes, Receptor-receptor interaction, Networks, Dopamine receptor, Serotonin 
receptor. 
INTRODUCTION 
The modulation of the binding characteristics, 
especially the affinity, of the monoamine receptors in a 
receptor subtype specific way by neuropeptides was 
tested in 1980-1981 and it opened the door to 
hypothesized the existence of an intramembrane 
receptor-receptor interactions phenomenon [1-10]. 
Thus, it was postulated that direct interactions may 
exist in addition to indirect actions via receptor 
phosphorylation, changes in the membrane potential or 
the involvement of adapter proteins [11-15]. Later on in 
1998-1999, it was demonstrated that two non-
functional GPCR receptors, GABAB1 and GABAB2 
protomers, can assemble in a signalling heterodimer at 
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of GPCR heteromerization [16, 17]. In addition, 
biophysical approaches (i.e. Fluorescence and 
Bioluminescence Resonance Energy Transfer 
methods, FRET and BRET respectively) provided the 
evidence needed to demonstrate the existence of 
GPCR heteroreceptor complexes in living cells [18-23]. 
In recent decades, a series of relevant contributions 
have demonstrated the importance of 
heterodimerization processes within the GPCR 
superfamily [18-20, 24-41].  
We have suggested that allosteric mechanisms, 
which make possible the integrative intermolecular 
activity, take place via the interface interaction in the 
homoreceptor or heteroreceptor complexes. As to the 
protomers interface we have observed a high energy 
strength double arginine-phosphate electrostatic 
interaction in the adenosine A2AR-dopamine D2R 
heteroreceptor complexes representing a hot spot in 
the protomer interface [41, 42]. The allosteric 
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mechanisms in the heteroreceptor complexes open up 
the door for a marked rise of the diversity of the 
GPCRs, e.g, their recognition, trafficking and signalling 
[20, 21, 39, 40, 43-48]. This is possible through 
modulation of the orthosteric/allosteric binding sites of 
the adjacent protomer, its G protein activation, its 
selectivity for scaffold protein recruitment and among 
others switching from G proteins to -arrestin 2 [43, 46, 
49-55]. The concept of moonlighting protein is 
employed to describe "multifunctional proteins in which 
several functions can be found in a single strand of 
amino acids unrelated to splicing, posttranslational 
changes etc" [56-58]. Moonlighting of GPCR 
heteroreceptor complexes may be brought about by the 
allosteric receptor-receptor interactions changing the 
function of the protomers of the heteroreceptor 
complexes [55, 59, 60]. The current state of the art in 
the brain dopamine D2 like, adenosine A2AR and 
serotonin 5-HT1AR heteroreceptor complexes will be 
described as well as some relevant methods/- 
techniques that could allow also the understanding of 
the balance between corresponding homo-and 
heteroreceptor complexes [61-63].  
THE OVERALL ARCHITECTURE OF THE GPCR-
GPCR HETERORECEPTOR COMPLEXES 
The entire number of demonstrated GPCR 
heteroreceptor complexes was linked together and 
represented as a GPCR heterodimer network (GPCR-
HetNet: http: //www.gpcr-hetnet.com/ [64]. In this study 
static/non-dynamical human GPCR data were manually 
collected with a total of 187 different nodes/protomers 
(until August 2014) derived from 537 GPCR-GPCR 
edges/interactions studies in databases and literature. 
These data were then integrated into a scale graph, 
which was named the GPCR heterodimer network 
(GPCR-HetNet), where the nodes are the 
heteroreceptor complexes protomers and the edges 
are the relationships or interactions between them. The 
analysis of the GPCR-HetNet indicate a scale free 
model in which only a few protomers dominate the 
connectivity and sustain the network together. Two hub 
criteria show that the growth hormone secretagogue 
receptor type 1, dopamine D2 receptor, the mu-type 
opioid receptor, the beta-2 adrenergic receptor, the 
secretin receptor, Cannabinoid receptor 1 and the 
delta-type opioid receptor are the hubs in the network. 
Other very well connected protomers are also observed 
and identified in this work, as well as the potential of 
existence of novel receptor-receptor interactions or the 
formation of higher order heteroreceptor complexes. In 
this study the overall architecture of the GPCR-GPCR 
heteroreceptor complexes is for the first time 
presented, which provides important insight into 
receptor-receptor interaction connectivity, topology and 
organization. And may contribute to a better 
understanding of the complexity of GPCR 
heteroreceptor systems [64]. 
Although in this work the homomer information was 
excluded, we have emphasized the facts that a high 
percent of the total protomers described exists as 
homomers. [64]. In lines with this evidence, it must be 
point out that by means of fluorescence correlation 
spectroscopy it has been demonstrated that biogenic 
amine receptors, freely diffusing within the plasma 
membrane, are predominantly homodimers and not 
monomers [65].  
The study of receptor-receptor interaction 
connectivity (intrafamily and interfamily) has also 
shown a significant prevalence of intrafamily versus 
interfamily connections [64]. We have claimed that one 
mechanism which could explain the marked dominance 
of intrafamily versus interfamily connections could be a 
favourable coevolution of the receptor-receptor 
interface interaction inside each subfamily. One 
characteristic of GPCRs subfamilies is the high 
sequence homologies/similarities of its member 
receptors and their reduced sequence homologies with 
other GPCR subfamilies [66]. For instance, Class B 
superfamily (Secretin-like), is suggested to have 
emerged from a single ancestral gene via gene 
duplication [67, 68]. As a result it shows a high 
sequence homology between its members [68]. 
Furthermore, it was demonstrated that homologues 
receptors belonging to the same subfamily can share 
similar interaction interfaces where their exposed 
residues can be either intermixed or run in parallel to 
one another [69]. Also, domain swapping phenomena 
can occur via their conserved domains/motifs, as have 
been shown for some GPCR heteroreceptor complexes 
[29, 30, 70]. Another reason could be the particular cell 
and tissue expression pattern of some GPCR [43, 47, 
71-75]. Some receptor classes, for instance TAS2R 
bitter taste receptors, are expressed in more restricted 
types of cells, tissues or organ than other receptors 
that are more widely expressed. Therefore, their 
members have a lower chance of encounters and 
interactions. Furthermore, a need for more 
experimental data who focus on the study of GPCR 
interfamily heteroreceptor complexes should be 
considered. So far, only a few groups have focused 
their efforts on the study of the specificity of GPCR 
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heteromer interactions, and we expect in a near future 
a more wide-spread existence of cross-family 
heterodimerization or a definite experimental 
confirmation of a lower number of inter family 
interactions, as shown in the analysis of GPCR-HetNet 
(http: //www.gpcr-hetnet.com/). 
It must be highlighted that the GPCR HetNet is so 
far the first and the only work that took into 
consideration not only a topological and architectural 
perspective of GPCR receptor-receptor interactions, 
but also the relevance of the specificities of the GPCR 
heteroreceptor complexes. In this database is 
presented in addition to the GPCR-GPCR interactions, 
that have been demonstrated experimentally by means 
of biophysical (BRET, FRET, FCCS) and biochemical 
(coimmunoprecipitation, in situ Proximity Ligation 
Assay (in situ PLA), and radioligand binding) methods, 
also their specificities and promiscuity. We have 
developed two networks, one represents the so called 
"positive receptor-receptor interaction" or GPCR 
HetNet and another one the GPCR Non-HetNet (see 
as well, http: //www.gpcr-hetnet.com/), which 
represents the experimentally demonstrated non-
interacting GPCR protomers. Relevant facts could be 
extrapolated from the comparison between both 
networks, like for example, the interaction pattern of the 
alpha-1D-adrenergic receptor, which shows a low level 
of connectivity in the HetNet but a high level of non-
interactions in the Non-HetNet.  
DOPAMINE D2-LIKE AND ADENOSINE A2A 
HETERORECEPTOR COMPLEXES 
There exists evidence for the presence of A2AR-
D2R heteroreceptor complexes not only in cell lines 
[41, 42, 63] but also in the rat striatum using the in situ 
PLA [71, 76] as well as indications for the existence of 
striatal A2AR-D3R and A2AR-D4R heteroreceptor 
complexes. Antagonistic A2AR-D2R interactions exist 
in the striatal A2AR-D2R heteroreceptor complexes 
reducing D2R recognition and signalling which has led 
to a novel understanding of the molecular bases behind 
the pathophysiology of drug addiction, Parkinson's 
diseases (PD) and L-DOPA-induced dyskinesias of 
high relevance for their treatments [52, 55, 63, 77-79]. 
Based on this, A2AR antagonists are being proposed in 
the symptomatic treatment of PD [52]. In line with these 
results A2AR agonists have been shown to have 
atypical antipsychotic actions and to possess anti-
cocaine actions in development and reinstatement of 
cocaine self-administration [77]. Also antagonistic 
CB1R-D2R interactions likely exist in striatal CB1R-
D2R heteromers leading to a reduced D2R signalling 
and counteraction of D2R-induced hyperlocomotion 
[80, 81]. Higher order heteromers may also be found 
since there are indications for the presence of striatal 
A2AR-CB1R-D2R trimers and A2AR-D2R-mGlu5R 
trimers with integrative receptor-receptor interactions 
modulating the activity of the striato-pallidal GABA 
neurons [82, 83]. In the latter trimer the A2AR and 
mGlu5R synergize to counteract the D2R signalling to 
allow firing of the striato-pallidal GABA neurons without 
being restrained by the inhibitory D2R signalling. In this 
way these receptors can potentially override a 
pathologically increased D2R signalling present in 
schizophrenia. In the former trimer the antagonistic 
CB1R-D2R interaction activated by endocannabinoids 
removes the D2 brake on the A2AR signalling to the 
adenylyl cyclase contributing to a markedly increased 
activity of the striato-pallidal GABA neurons [81]. The 
A2AR-CB1R-D2R trimer may function mainly as an 
inhibitory feedback mechanism to reduce an 
exaggerated and prolonged activation of D2R removing 
an excessive silencing of the striato-pallidal GABA 
neurons. Thus, these two types of GPCR trimers are 
also potential novel drug targets for treatment of PD, 
schizophrenia and cocaine addiction. 
SEROTONIN 5-HT1A HETERORECEPTOR COM- 
PLEXES 
As to the 5-HT1AR heteroreceptor complexes 
evidence exists that Galanin receptor1 (GalR1) 
modulates 5-HT1AR signalling via heterodimerization 
in cellular models [21]. These results amplify the 
indications that there exist brain GalR1-5-HT1AR 
heteromers in which the previously observed 
antagonistic galaninR-5-HT1A receptor-receptor 
interactions in the limbic system take place [84]. 
Targeting different types GalR-5-HT1AR heteromers 
may be a novel therapeutic strategy for treatment of 
depression [53, 72, 84]. Targeting the recently 
discovered FGFR1-5-HT1AR heteroreceptor 
complexes of the hippocampus may be another 
therapeutic approach in depression in view of their 
enhancement of hippocampal plasticity [75, 85]. 
Combined acute and repeated intracerebrocentricular 
treatment with FGF2 and 8-OH-DPAT have shown 
evidence as significant antidepressant in the forced 
swim test [75]. These heteroreceptor complexes were 
also observed in midbrain 5-HT neurons of the rat [73]. 
The 5-HT1A autoreceptor protomer upon agonist 
activation produced an allosteric enhancement of the 
FGFR1 signaling in the midbrain raphe 5-HT nerve 
cells leading to increases in their neuroplasticity and 
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trophism. Thus, the 5-HT1A autoreceptor in this 
heteroreceptor complex can also have a trophic role of 
importance for depression and its treatment in addition 
to its key role in reducing the firing of the ascending 
midbrain 5-HT neurons. 
New findings have shown that combine treatment 
with 8-OH-DPAT and FGF2 but not treatment with the 
5-HT1A agonist alone significantly increases the 
BRETmax values and markedly reduces the BRET50 
values on the 5HT1A homodimerization in cellular 
models co-expressing 5-HT1A and FGFR1 [86]. FGF2 
produces a rapid rise in FGFR1 homodimerization 
which, to certain extent, declined over a 10 min period. 
Combine treatment with 8-OH-DPAT blocked this 
decline in FGFR1 homodimerization. Also, it was 
observed that FGF2 only produced a small rise in the 
BRET
2
 signal from the 5-HT1A--arrestin2 complex 
which was additive to the significant effect of 8-OH-
DPAT alone. All together, these results have shown a 
dynamic modulation of the allosteric receptor-receptor 
interactions in the FGFR1-5-HT1A heteroreceptor 
complexes with regard to their impact on 5-HT1AR and 
FGFR1 homodimerization [86]. 
METHODS FOR STUDYING GPCR RECEPTOR-
RECEPTOR INTERACTIONS  
In the last years, interactions involving GPCRs were 
demonstrated through diverse biophysical (FRET, 
BRET, BiFC) and biochemical or microscopy-based 
procedures (e.g. coimmunolocalization, coimmuno- 
precipitation, radioligand binding, co-internalization 
analysis) including methods that assess receptor-
receptor interactions [22, 23, 85, 87, 88]. Each 
methods or tools employed has gave a precise and 
valuable information which has been considered with 
caution to avoid undesirable drawbacks. Some 
controversy regarding some approaches have also 
emerged [89, 90]. Nevertheless, when these methods 
are properly assessed it is possible to demonstrate 
elegantly the direct interactions between GPCRs and 
as well as their dynamics. [91-93]. 
Novel technologies to study receptor heteroreceptor 
complexes and their receptor-receptor interactions 
have recently been developed such as real-time FRET 
experiments in living cells [94], dual-colour 
fluorescence cross-correlation spectroscopy (FCCS) 
[65] and mass spectrometry of phosphorylation 
fingerprints from receptor protomers of receptor 
heteromer and homomers [95]. A new dimension in the 
GPCR heteromer field was also introduced in 2010 by 
the evidence obtained, in cellular models first [48] and 
in brain tissue later [43, 46, 47, 72-76, 85], of the 
existence of GPCR heteroreceptor complexes by 
means of the in situ PLA. This method offers the 
advantages of the analysis of any receptor-receptor 
interactions for which suitable antibodies are available 
without using genetic constructs. As with any method 
there are limitations, for instance, in situ PLA could only 
be used in ex vivo fixed material. The method strongly 
relies on the quality of the antibodies used, and we 
must take into account parameters such as antibody 
concentration, epitopes targeted by the antibodies, 
fixation, antigen-retrieval, blocking conditions, etc. 
ON THE UNDERSTANDING OF THE BALANCE 
BETWEEN THE HOMO-AND HETERORECEPTOR 
COMPLEXES IN THE BRAIN 
Until now, most experimental work was focused on 
the study of GPCR receptor-receptor interactions as a 
phenomenon of binary interactions. In other words, it 
was only focused on the understanding of face-to-face 
protomer-protomer interactions and their allosteric 
receptor-receptor modulation and functional 
specificities (See www.gpcr-hetnet.com [64] for a 
complete list of all binary pairs of GPCR-GPCR 
interactions described so far). However, the 
phenomenon of GPCR oligomerization is a more 
complex and dynamic process, which involve many 
more parameters than the classical analysis of the 
interactions of the two involved protomers [86]. One 
emerging concept is that direct physical receptor-
receptor interactions in heteroreceptor complexes or 
altered balance with their homoreceptor complexes 
population can contribute to brain disease progression 
inter alias PD, depression, Schizophrenia, Alzheimer 
and addiction [61, 79]. When discussing the role of 
GPCR heteroreceptor complexes, it is of substantial 
interest to understand the balance/equilibrium between 
the corresponding homo- and heteroreceptor 
complexes in the plasma membrane of the cell (Figure 
1). It should be important to also consider a disruption 
or shift of the balance between corresponding receptor 
homomers and heteromer populations as a mechanism 
for disease development which therefore also 
represents a pharmacological target. 
 We have suggested that the introduction of in situ PLA 
(Figure 1) in combination with western blot, radioligand 
binding experiments and co-immunoprocipitation could 
open a new window to the understanding of the 
importance of the balance of the corresponding homo-
and heteroreceptor complexes [85]. The analysis of 
animal/human brain material with in situ PLA can 
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reveal if the relative abundance of specific homo-and 
heteroreceptor complexes in discrete brain regions is 
altered in brain diseases or under certain drug 
treatments, for instance, chronic L-dopa treatment in 
PD [61, 79].  
In this analysis, it is important also to determine the 
ratio between heteromers versus total number of the 
two participating receptor populations, using in addition 
to Western blots, receptor autoradiography and 
biochemical binding methods. The two latter methods 
show the densities and affinities of the two functional 
receptor populations. The relationship between these 
parameters will help to normalize the heteromer values 
for comparison between groups in addition to 
evaluating the potential changes in the total number of 
the two receptor populations [85].  
Certainly, we cannot compare or determine directly 
a balance between the homo- and heteroreceptor 
complexes populations in the same tissue using the in 
situ PLA approach, because of a technical limitation of 
the procedure itself. But the method could help us 
determine each population independently and compare 
their relative expression levels after an appropriate 
numerical analysis. Furthermore, it should help 
understand the effects that could be induced by 
agonist/antagonist treatments on the regulation of 
these homo-/heteroreceptor complexes in order to 
understand their potential roles as drug targets or as 
markers of brain disease progression. 
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Figure 1: On the understanding of the balance/equilibrium between GPCR homo- and heteroreceptor complexes population in 
the neuron membrane in the brain. (Top right) Schematic representation of the balance between different populations of homo 
and hetero-receptor complexes in a portion of the membrane cell. (Bottom) The panel represent an example of in situ PLA 
experiment performed in rat hippocampal free-floating sections using primary antibodies of different species directed to 
adenosine A2A and A2B receptors. The detected A2A-A2B heteroreceptor complexes are seen as red clusters indicated by 
arrows in each panel. Specific A2A-A2B clusters are visualized within discrete regions of the pyramidal cell layer of the 
Ammon´s horn and the molecular cell layer of the dentate gyros (ventral leaflet). The complex was also observed throughout the 
cortex and in the piriforme layer but were almost absent in the molecular cell layer of the dentate gyros (dorsal leaflet). The 
analysis of animal/human brain material with in situ PLA can reveal if the relative abundance of specific homo- heteroreceptor 
complexes in discrete brain regions is altered in brain diseases or under certain drug treatments. 
On the Role of the Balance of Gpcr Homo/ Heteroreceptor Complexes in the Brain Journal of Advanced Neuroscience Research, 2015, Vol. 2, No. 1  41 
by the Swedish Medical Research Council (62X-00715-
50-3) and AFA Försäkring (130328) to KF and D.O.B-
E. I.B and D.O.B-E belong to Academia de Biólogos 
Cubanos.  
CONFLICTS OF INTEREST 
The authors declare no conflict of interest 
REFERENCES 
[1] Fuxe K, Agnati LF, Benfenati F, Cimmino M, Algeri S, Hokfelt 
T, et al. Modulation by cholecystokinins of 3H-spiroperidol 
binding in rat striatum: evidence for increased affinity and 
reduction in the number of binding sites. Acta Physiol Scand 
1981 Dec; 113(4): 567-9. 
[2] Agnati LF, Fuxe K, Zoli M, Rondanini C, Ogren SO. New 
vistas on synaptic plasticity: the receptor mosaic hypothesis 
of the engram. Med Biol 1982 Aug; 60(4): 183-90. 
[3] Fuxe K, Agnati LF, Benfenati F, Celani M, Zini I, Zoli M, et al. 
Evidence for the existence of receptor--receptor interactions 
in the central nervous system. Studies on the regulation of 
monoamine receptors by neuropeptides. J Neural Transm 
Suppl 1983; 18: 165-79. 
[4] Agnati LF, Celani MF, Fuxe K. Cholecystokinin peptides in 
vitro modulate the characteristics of the striatal 3H-N-
propylnorapomorphine sites. Acta Physiol Scand 1983 May; 
118(1): 79-81. 
[5] Agnati LF, Fuxe K, Benfenati F, Celani MF, Battistini N, Mutt 
V, et al. Differential modulation by CCK-8 and CCK-4 of 
[3H]spiperone binding sites linked to dopamine and 5-
hydroxytryptamine receptors in the brain of the rat. Neurosci 
Lett 1983 Feb 21; 35(2): 179-83. 
[6] Agnati LF, Fuxe K, Benfenati F, Battistini N, Harfstrand A, 
Tatemoto K, et al. Neuropeptide Y in vitro selectivity 
increases the number of alpha 2-adrenergic binding sites in 
membranes of the medulla oblongata of the rat. Acta Physiol 
Scand 1983 Jul; 118(3): 293-5. 
[7] Fuxe K, Celani MF, Martire M, Zini I, Zoli M, Agnati LF. l-
Glutamate reduces the affinity of [3H]N-
propylnorapomorphine binding sites in striatal membranes. 
Eur J Pharmacol 1984 Apr 13; 100(1): 127-30. 
[8] Fuxe K, Agnati LF. Receptor-receptor interactions in the 
central nervous system. A new integrative mechanism in 
synapses. Med Res Rev 1985 Oct-Dec; 5(4): 441-82. 
[9] Fuxe K, Agnati LF. Receptor-receptor interactions. A new 
intramembrane integrative mechanisms. London: McMillan 
Press; 1987. 
[10] Fuxe K, Von Euler G, Agnati LF. Angiotensin II reduces the 
affinity of [3H]para-aminoclonidine binding sites in membrane 
preparations from the rat dorsomedial medulla oblongata. 
Acta Physiol Scand 1988 Oct; 134(2): 317-8. 
[11] Bockaert J, Marin P, Dumuis A, Fagni L. The 'magic tail' of G 
protein-coupled receptors: an anchorage for functional 
protein networks. FEBS Lett 2003 Jul 3; 546(1): 65-72. 
[12] Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting 
proteins (GIP). Pharmacol Ther 2004 Sep; 103(3): 203-21. 
[13] Bockaert J, Perroy J, Becamel C, Marin P, Fagni L. GPCR 
interacting proteins (GIPs) in the nervous system: Roles in 
physiology and pathologies. Annu Rev Pharmacol Toxicol 
2010; 50: 89-109. 
[14] Borroto-Escuela DO, Correia PA, Romero-Fernandez W, 
Narvaez M, Fuxe K, Ciruela F, et al. Muscarinic receptor 
family interacting proteins: Role in receptor function. J 
Neurosci Methods 2010 Feb 15; 195(2): 161-9. 
[15] Borroto-Escuela DO, Correia PA, Perez Alea M, Narvaez M, 
Garriga P, Fuxe K, et al. Impaired M(3) muscarinic 
acetylcholine receptor signal transduction through blockade 
of binding of multiple proteins to its third intracellular loop. 
Cell Physiol Biochem 2010; 25(4-5): 397-408. 
[16] Marshall FH, White J, Main M, Green A, Wise A. GABA(B) 
receptors function as heterodimers. Biochem Soc Trans 1999 
Aug; 27(4): 530-5. 
[17] Marshall FH, Jones KA, Kaupmann K, Bettler B. GABAB 
receptors - the first 7TM heterodimers. Trends Pharmacol Sci 
1999 Oct; 20(10): 396-9. 
[18] Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis 
M, et al. Detection of beta 2-adrenergic receptor dimerization 
in living cells using bioluminescence resonance energy 
transfer (BRET). Proceedings of the National Academy of 
Sciences of the United States of America 2000 Mar 28; 
97(7): 3684-9. 
[19] Angers S, Salahpour A, Bouvier M. Biochemical and 
biophysical demonstration of GPCR oligomerization in 
mammalian cells. Life sciences 2001 Apr 6; 68(19-20): 2243-
50. 
[20] Borroto-Escuela DO, Garcia-Negredo G, Garriga P, Fuxe K, 
Ciruela F. The M(5) muscarinic acetylcholine receptor third 
intracellular loop regulates receptor function and 
oligomerization. Biochim Biophys Acta 2010 Jul; 1803(7): 
813-25. 
[21] Borroto-Escuela DO, Narvaez M, Marcellino D, Parrado C, 
Narvaez JA, Tarakanov AO, et al. Galanin receptor-1 
modulates 5-hydroxtryptamine-1A signaling via 
heterodimerization. Biochem Biophys Res Commun 2010 
Mar 19; 393(4): 767-72. 
[22] Fernandez-Duenas V, Llorente J, Gandia J, Borroto-Escuela 
DO, Agnati LF, Tasca CI, et al. Fluorescence resonance 
energy transfer-based technologies in the study of protein-
protein interactions at the cell surface. Methods 2012 Aug; 
57(4): 467-72. 
[23] Borroto-Escuela DO, Flajolet M, Agnati LF, Greengard P, 
Fuxe K. Bioluminescence resonance energy transfer 
methods to study G protein-coupled receptor-receptor 
tyrosine kinase heteroreceptor complexes. Methods in cell 
biology 2013; 117: 141-64. 
[24] Fuxe K, Ferre S, Zoli M, Agnati LF. Integrated events in 
central dopamine transmission as analyzed at multiple levels. 
Evidence for intramembrane adenosine A2A/dopamine D2 
and adenosine A1/dopamine D1 receptor interactions in the 
basal ganglia. Brain Res Brain Res Rev 1998 May; 26(2-3): 
258-73. 
[25] Franco R, Ferre S, Agnati L, Torvinen M, Gines S, Hillion J, 
et al. Evidence for adenosine/dopamine receptor 
interactions: indications for heteromerization. 
Neuropsychopharmacology : official publication of the 
American College of Neuropsychopharmacology 2000 Oct; 
23(4 Suppl): S50-9. 
[26] Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela 
EI, et al. Dopamine D1 and adenosine A1 receptors form 
functionally interacting heteromeric complexes. Proceedings 
of the National Academy of Sciences of the United States of 
America 2000 Jul 18; 97(15): 8606-11. 
[27] Hebert TE, Loisel TP, Adam L, Ethier N, Onge SS, Bouvier 
M. Functional rescue of a constitutively desensitized 
beta2AR through receptor dimerization. The Biochemical 
journal 1998 Feb 15; 330 ( Pt 1): 287-93. 
[28] Dean MK, Higgs C, Smith RE, Bywater RP, Snell CR, Scott 
PD, et al. Dimerization of G-protein-coupled receptors. 
Journal of medicinal chemistry 2001 Dec 20; 44(26): 4595-
614. 
[29] Gouldson PR, Higgs C, Smith RE, Dean MK, Gkoutos GV, 
Reynolds CA. Dimerization and domain swapping in G-
protein-coupled receptors: a computational study. 
42 Journal of Advanced Neuroscience Research, 2015, Vol. 2, No. 1 Borroto-Escuela et al. 
Neuropsychopharmacology : official publication of the 
American College of Neuropsychopharmacology 2000 Oct; 
23(4 Suppl): S60-77. 
[30] Gouldson PR, Snell CR, Bywater RP, Higgs C, Reynolds CA. 
Domain swapping in G-protein coupled receptor dimers. 
Protein engineering 1998 Dec; 11(12): 1181-93. 
[31] Devi LA. Heterodimerization of G-protein-coupled receptors: 
pharmacology, signaling and trafficking. Trends Pharmacol 
Sci 2001 Oct; 22(10): 532-7. 
[32] Kenakin T. Drug efficacy at G protein-coupled receptors. 
Annu Rev Pharmacol Toxicol 2002; 42: 349-79. 
[33] Lee SP, Xie Z, Varghese G, Nguyen T, O'Dowd BF, George 
SR. Oligomerization of dopamine and serotonin receptors. 
Neuropsychopharmacology : official publication of the 
American College of Neuropsychopharmacology 2000 Oct; 
23(4 Suppl): S32-40. 
[34] Xie Z, Lee SP, O'Dowd BF, George SR. Serotonin 5-HT1B 
and 5-HT1D receptors form homodimers when expressed 
alone and heterodimers when co-expressed. FEBS Lett 1999 
Jul 30; 456(1): 63-7. 
[35] Zeng F, Wess J. Molecular aspects of muscarinic receptor 
dimerization. Neuropsychopharmacology : official publication 
of the American College of Neuropsychopharmacology 2000 
Oct; 23(4 Suppl): S19-31. 
[36] Overton MC, Blumer KJ. G-protein-coupled receptors 
function as oligomers in vivo. Current biology : CB 2000 Mar 
23; 10(6): 341-4. 
[37] Portoghese PS. From models to molecules: opioid receptor 
dimers, bivalent ligands, and selective opioid receptor 
probes. Journal of medicinal chemistry 2001 Jul 5; 44(14): 
2259-69. 
[38] Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, 
Kostenis E, et al. A heterodimer-selective agonist shows in 
vivo relevance of G protein-coupled receptor dimers. 
Proceedings of the National Academy of Sciences of the 
United States of America 2005 Jun 21; 102(25): 9050-5. 
[39] Borroto-Escuela DO, Craenenbroeck KV, Romero-Fernandez 
W, Guidolin D, Woods AS, Rivera A, et al. Dopamine D2 and 
D4 receptor heteromerization and its allosteric receptor-
receptor interactions. Biochem Biophys Res Commun 2010 
Jan 28; 404(4): 928-34. 
[40] Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, 
Marcellino D, Ciruela F, Agnati LF, et al. Dopamine D2 and 
5-hydroxytryptamine 5-HT(A) receptors assemble into 
functionally interacting heteromers. Biochem Biophys Res 
Commun 2010 Oct 29; 401(4): 605-10. 
[41] Borroto-Escuela DO, Marcellino D, Narvaez M, Flajolet M, 
Heintz N, Agnati L, et al. A serine point mutation in the 
adenosine A2AR C-terminal tail reduces receptor 
heteromerization and allosteric modulation of the dopamine 
D2R. Biochem Biophys Res Commun 2010 Mar 26; 394(1): 
222-7. 
[42] Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, 
Gomez-Soler M, Corrales F, Marcellino D, et al. 
Characterization of the A2AR-D2R interface: focus on the 
role of the C-terminal tail and the transmembrane helices. 
Biochem Biophys Res Commun 2010 Nov 26; 402(4): 801-7. 
[43] Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, 
Oflijan J, Agnati LF, Fuxe K. Hallucinogenic 5-HT2AR 
agonists LSD and DOI enhance dopamine D2R protomer 
recognition and signaling of D2-5-HT2A heteroreceptor 
complexes. Biochem Biophys Res Commun 2014 Jan 3; 
443(1): 278-84. 
[44] Ferraro L, Beggiato S, Borroto-Escuela DO, Ravani L, 
O'Connor WT, Tomasini MC, et al. Neurotensin NTS1-
dopamine D2 receptor-receptor interactions in putative 
receptor heteromers: relevance for Parkinson's disease and 
schizophrenia. Current protein & peptide science 2014; 
15(7): 681-90. 
[45] Van Craenenbroeck K, Borroto-Escuela DO, Skieterska K, 
Duchou J, Romero-Fernandez W, Fuxe K. Role of 
dimerization in dopamine D(4) receptor biogenesis. Current 
protein & peptide science 2014; 15(7): 659-65. 
[46] Borroto-Escuela DO, Narvaez M, Di Palma M, Calvo F, 
Rodriguez D, Millon C, et al. Preferential activation by 
galanin 1-15 fragment of the GalR1 protomer of a GalR1-
GalR2 heteroreceptor complex. Biochem Biophys Res 
Commun 2014 Sep 26; 452(3): 347-53. 
[47] Romero-Fernandez W, Borroto-Escuela DO, Agnati LF, Fuxe 
K. Evidence for the existence of dopamine D2-oxytocin 
receptor heteromers in the ventral and dorsal striatum with 
facilitatory receptor-receptor interactions. Molecular 
psychiatry 2013 Aug; 18(8): 849-50. 
[48] Borroto-Escuela DO, Van Craenenbroeck K, Romero-
Fernandez W, Guidolin D, Woods AS, Rivera A, et al. 
Dopamine D2 and D4 receptor heteromerization and its 
allosteric receptor-receptor interactions. Biochem Biophys 
Res Commun 2010 Jan 28; 404(4): 928-34. 
[49] Fuxe K, Marcellino D, Borroto-Escuela DO, Frankowska M, 
Ferraro L, Guidolin D, et al. The changing world of G protein-
coupled receptors: from monomers to dimers and receptor 
mosaics with allosteric receptor-receptor interactions. J 
Recept Signal Transduct Res 2010 Oct; 30(5): 272-83. 
[50] Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, 
Ciruela F, Agnati LF, Fuxe K. On the existence of a possible 
A2A-D2-beta-Arrestin2 complex: A2A agonist modulation of 
D2 agonist-induced beta-arrestin2 recruitment. J Mol Biol 
2011 Mar 11; 406(5): 687-99. 
[51] Fuxe K, Borroto-Escuela DO, Marcellino D, Romero-
Fernandez W, Frankowska M, Guidolin D, et al. GPCR 
heteromers and their allosteric receptor-receptor interactions. 
Curr Med Chem 2012; 19(3): 356-63. 
[52] Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO. 
Dopamine heteroreceptor complexes as therapeutic targets 
in Parkinson's disease. Expert opinion on therapeutic targets 
2014 Dec 8: 1-22. 
[53] Fuxe K, Borroto-Escuela D, Fisone G, Agnati LF, Tanganelli 
S. Understanding the role of heteroreceptor complexes in the 
central nervous system. Current protein & peptide science 
2014; 15(7): 647. 
[54] Fuxe K, Agnati LF, Borroto-Escuela DO. The impact of 
receptor-receptor interactions in heteroreceptor complexes 
on brain plasticity. Expert review of neurotherapeutics 2014 
Jul; 14(7): 719-21. 
[55] Fuxe K, Tarakanov A, Romero Fernandez W, Ferraro L, 
Tanganelli S, Filip M, et al. Diversity and Bias through 
Receptor-Receptor Interactions in GPCR Heteroreceptor 
Complexes. Focus on Examples from Dopamine D2 
Receptor Heteromerization. Frontiers in endocrinology 2014; 
5: 71. 
[56] Jeffery CJ. Moonlighting proteins--an update. Mol Biosyst 
2009 Apr; 5(4): 345-50. 
[57] Jeffery CJ. Molecular mechanisms for multitasking: recent 
crystal structures of moonlighting proteins. Curr Opin Struct 
Biol 2004 Dec; 14(6): 663-8. 
[58] Jeffery CJ. Moonlighting proteins: old proteins learning new 
tricks. Trends Genet 2003 Aug; 19(8): 415-7. 
[59] Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, 
Palkovits M, Tarakanov AO, Ciruela F, et al. Moonlighting 
proteins and protein-protein interactions as neurotherapeutic 
targets in the G protein-coupled receptor field. 
Neuropsychopharmacology : official publication of the 
American College of Neuropsychopharmacology 2014 Jan; 
39(1): 131-55. 
[60] Borroto-Escuela DO, Tarakanov AO, Guidolin D, Ciruela F, 
Agnati LF, Fuxe K. Moonlighting characteristics of G protein-
coupled receptors: focus on receptor heteromers and 
relevance for neurodegeneration. IUBMB Life 2011 Jul; 
63(7): 463-72. 
On the Role of the Balance of Gpcr Homo/ Heteroreceptor Complexes in the Brain Journal of Advanced Neuroscience Research, 2015, Vol. 2, No. 1  43 
[61] Antonelli T, Fuxe K, Agnati L, Mazzoni E, Tanganelli S, 
Tomasini MC, et al. Experimental studies and theoretical 
aspects on A2A/D2 receptor interactions in a model of 
Parkinson's disease. Relevance for L-dopa induced 
dyskinesias. Journal of the neurological sciences 2006 Oct 
25; 248(1-2): 16-22. 
[62] Fuxe K, Marcellino D, Genedani S, Agnati L. Adenosine 
A(2A) receptors, dopamine D(2) receptors and their 
interactions in Parkinson's disease. Movement disorders : 
official journal of the Movement Disorder Society 2007 Oct 
31; 22(14): 1990-2017. 
[63] Fuxe K, Marcellino D, Borroto-Escuela DO, Guescini M, 
Fernandez-Duenas V, Tanganelli S, et al. Adenosine-
dopamine interactions in the pathophysiology and treatment 
of CNS disorders. CNS Neurosci Ther 2010 Jun; 16(3): e18-
42. 
[64] Borroto-Escuela DO, Brito I, Romero-Fernandez W, Di Palma 
M, Oflijan J, Skieterska K, et al. The G protein-coupled 
receptor heterodimer network (GPCR-HetNet) and its hub 
components. International journal of molecular sciences 
2014; 15(5): 8570-90. 
[65] Herrick-Davis K, Grinde E, Cowan A, Mazurkiewicz JE. 
Fluorescence correlation spectroscopy analysis of serotonin, 
adrenergic, muscarinic, and dopamine receptor dimerization: 
the oligomer number puzzle. Molecular pharmacology 2013 
Oct; 84(4): 630-42. 
[66] Attwood TK, Findlay JB. Fingerprinting G-protein-coupled 
receptors. Protein engineering 1994 Feb; 7(2): 195-203. 
[67] Cardoso JC, Vieira FA, Gomes AS, Power DM. The 
serendipitous origin of chordate secretin peptide family 
members. BMC evolutionary biology 2010; 10: 135. 
[68] Cardoso JC, Pinto VC, Vieira FA, Clark MS, Power DM. 
Evolution of secretin family GPCR members in the metazoa. 
BMC evolutionary biology 2006; 6: 108. 
[69] Sukhwal A, Sowdhamini R. Oligomerisation status and 
evolutionary conservation of interfaces of protein structural 
domain superfamilies. Mol Biosyst 2013 Jul; 9(7): 1652-61. 
[70] Havlickova M, Prezeau L, Duthey B, Bettler B, Pin JP, Blahos 
J. The intracellular loops of the GB2 subunit are crucial for G-
protein coupling of the heteromeric gamma-aminobutyrate B 
receptor. Molecular pharmacology 2002 Aug; 62(2): 343-50. 
[71] Borroto-Escuela DO, Romero-Fernandez W, Pere G, Ciruela 
F, Narvaez M, Tarakanov AO, et al. G-Protein Coupled 
Receptor Heterodimerization in the Brain. In: Conn M, editor. 
G Protein Coupled Receptors. Methods in Enzymology. 521: 
Academic Press; 2013. p. 480. 
[72] Millon C, Flores-Burgess A, Narvaez M, Borroto-Escuela DO, 
Santin L, Parrado C, et al. A Role For Galanin N-Terminal 
Fragment (1-15) In Anxiety- And Depression-Related 
Behaviours In Rats. The international journal of 
neuropsychopharmacology / official scientific journal of the 
Collegium Internationale Neuropsychopharmacologicum 
2014 Oct 31. 
[73] Borroto-Escuela DO, Narvaez M, Perez-Alea M, Tarakanov 
AO, Jimenez-Beristain A, Mudo G, et al. Evidence for the 
existence of FGFR1-5-HT1A heteroreceptor complexes in 
the midbrain raphe 5-HT system. Biochem Biophys Res 
Commun 2014 Dec 6. 
[74] Narvaez M, Millon C, Borroto-Escuela D, Flores-Burgess A, 
Santin L, Parrado C, et al. Galanin receptor 2-neuropeptide Y 
Y1 receptor interactions in the amygdala lead to increased 
anxiolytic actions. Brain structure & function 2014 May 20. 
[75] Borroto-Escuela DO, Romero-Fernandez W, Mudo G, Perez-
Alea M, Ciruela F, Tarakanov AO, et al. Fibroblast Growth 
Factor Receptor 1- 5-Hydroxytryptamine 1A Heteroreceptor 
Complexes and Their Enhancement of Hippocampal 
Plasticity. Biol Psychiatry 2012 Jan 1; 71(1): 84-91. 
[76] Trifilieff P, Rives ML, Urizar E, Piskorowski RA, Vishwasrao 
HD, Castrillon J, et al. Detection of antigen interactions ex 
vivo by proximity ligation assay: endogenous dopamine D2-
adenosine A2A receptor complexes in the striatum. 
Biotechniques 2011 Aug; 51(2): 111-8. 
[77] Wydra K, Suder A, Borroto-Escuela DO, Filip M, Fuxe K. On 
the role of A and D receptors in control of cocaine and food-
seeking behaviors in rats. Psychopharmacology 2014 Nov 
26. 
[78] Guidolin D, Agnati LF, Marcoli M, Borroto-Escuela DO, Fuxe 
K. G-protein-coupled receptor type A heteromers as an 
emerging therapeutic target. Expert opinion on therapeutic 
targets 2014 Nov 10: 1-19. 
[79] Fuxe K, Borroto-Escuela DO, Tarakanov AO, Romero-
Fernandez W, Ferraro L, Tanganelli S, et al. Dopamine D2 
heteroreceptor complexes and their receptor-receptor 
interactions in ventral striatum: novel targets for antipsychotic 
drugs. Progress in brain research 2014; 211: 113-39. 
[80] Agnati LF, Guidolin D, Albertin G, Trivello E, Ciruela F, 
Genedani S, et al. An integrated view on the role of receptor 
mosaics at perisynaptic level: focus on adenosine A(2A), 
dopamine D(2), cannabinoid CB(1), and metabotropic 
glutamate mGlu(5) receptors. J Recept Signal Transduct Res 
2010 Oct; 30(5): 355-69. 
[81] Fuxe K, Marcellino D, Rivera A, Diaz-Cabiale Z, Filip M, 
Gago B, et al. Receptor-receptor interactions within receptor 
mosaics. Impact on neuropsychopharmacology. Brain Res 
Rev 2008 Aug; 58(2): 415-52. 
[82] Cabello N, Gandia J, Bertarelli DC, Watanabe M, Lluis C, 
Franco R, et al. Metabotropic glutamate type 5, dopamine D2 
and adenosine A2a receptors form higher-order oligomers in 
living cells. J Neurochem 2009 Jun; 109(5): 1497-507. 
[83] Carriba P, Navarro G, Ciruela F, Ferre S, Casado V, Agnati 
L, et al. Detection of heteromerization of more than two 
proteins by sequential BRET-FRET. Nat Methods 2008 Aug; 
5(8): 727-33. 
[84] Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, 
Tarakanov AO, Calvo F, Garriga P, et al. On the existence 
and function of galanin receptor heteromers in the central 
nervous system. Frontiers in endocrinology 2012; 3: 127. 
[85] Borroto-Escuela DO, Romero-Fernandez W, Garriga P, 
Ciruela F, Narvaez M, Tarakanov AO, et al. G protein-
coupled receptor heterodimerization in the brain. Methods in 
enzymology 2013; 521: 281-94. 
[86] Borroto-Escuela DO, Corrales F, Narvaez M, Oflijan J, Agnati 
LF, Palkovits M, et al. Dynamic modulation of FGFR1-5-
HT1A heteroreceptor complexes. Agonist treatment 
enhances participation of FGFR1 and 5-HT1A homodimers 
and recruitment of beta-arrestin2. Biochem Biophys Res 
Commun 2013 Nov 15; 441(2): 387-92. 
[87] Skieterska K, Duchou J, Lintermans B, Van Craenenbroeck 
K. Detection of G protein-coupled receptor (GPCR) 
dimerization by coimmunoprecipitation. Methods in cell 
biology 2013; 117: 323-40. 
[88] Achour L, Kamal M, Jockers R, Marullo S. Using quantitative 
BRET to assess G protein-coupled receptor homo- and 
heterodimerization. Methods in molecular biology 2011; 756: 
183-200. 
[89] James JR, Oliveira MI, Carmo AM, Iaboni A, Davis SJ. A 
rigorous experimental framework for detecting protein 
oligomerization using bioluminescence resonance energy 
transfer. Nat Methods 2006 Dec; 3(12): 1001-6. 
[90] Bouvier M, Heveker N, Jockers R, Marullo S, Milligan G. 
BRET analysis of GPCR oligomerization: newer does not 
mean better. Nat Methods 2007 Jan; 4(1): 3-4; author reply  
[91] Marullo S, Bouvier M. Resonance energy transfer 
approaches in molecular pharmacology and beyond. Trends 
Pharmacol Sci 2007 Aug; 28(8): 362-5. 
[92] Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, 
et al. International Union of Basic and Clinical Pharmacology. 
LXVII. Recommendations for the recognition and 
44 Journal of Advanced Neuroscience Research, 2015, Vol. 2, No. 1 Borroto-Escuela et al. 
nomenclature of G protein-coupled receptor heteromultimers. 
Pharmacological reviews 2007 Mar; 59(1): 5-13. 
[93] Audet M, Lagace M, Silversides DW, Bouvier M. Protein-
protein interactions monitored in cells from transgenic mice 
using bioluminescence resonance energy transfer. FASEB 
journal : official publication of the Federation of American 
Societies for Experimental Biology 2010 Aug; 24(8): 2829-38. 
[94] Fernandez-Duenas V, Gomez-Soler M, Jacobson KA, 
Santhosh Kumar T, Fuxe K, Borroto-Escuela DO, et al. 
Molecular determinants of a(2a) r-d(2) r allosterism: Role of 
the intracellular loop 3 of the d(2) r. J Neurochem 2012 Aug 
28. 
[95] Butcher AJ, Prihandoko R, Kong KC, McWilliams P, Edwards 
JM, Bottrill A, et al. Differential G-protein-coupled receptor 
phosphorylation provides evidence for a signaling bar code. 
The Journal of biological chemistry 2011 Apr 1; 286(13): 
11506-18. 
 
Received on 26-12-2014 Accepted on 30-01-2015 Published on 14-04-2015 
 
http://dx.doi.org/10.15379/2409-3564.2015.02.01.5 
© 2015 Borroto-Escuela et al.; Licensee Cosmos Scholars Publishing House. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, 
provided the work is properly cited. 
